The largest database of trusted experimental protocols

Navitoclax

Manufactured by Merck Group
Sourced in Israel

Navitoclax is a small-molecule drug candidate developed by Merck Group. It functions as a selective inhibitor of the B-cell lymphoma 2 (Bcl-2) family of proteins, which play a role in regulating apoptosis, or programmed cell death.

Automatically generated - may contain errors

2 protocols using navitoclax

1

Pre-miR-21 Folding and Compound Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Unmodified, desalted, and HPLC purified pre-miR-21 was purchased
from Eurofins Scientific (Louisville, KY, USA). RNA was folded via
resuspending with buffer (10 mM Tris-HCl pH 7.5 with 20 mM NaCl), and heated
to 95°C for 90 sec, and allowed to cool to room temperature
overnight. Folded RNA was aliquoted and stored in −20°C until
assayed. The following sequence of pre-miR-21 was purchased:
5’-UGUCGGGUAGCUUAUCAGACUGAUGUUGACUGUUGAAUCUCAUGGCAACACCAGUCGAUGGGCU
GUCUGACA-3’
Butylcycloheptyl prodiginine (bPGN) was supplied by Developmental
Therapeutics Program (DTP), Division of Cancer Treatment and Diagnosis in
the National Cancer Institute (NCI). Plates for high-throughput screens were
provided by NCI, Molecular Targets Program (MTP). Compounds such as 5-FU,
obatoclax, prodigiosin, navitoclax, spermidine, methoctramine,
hexachlotophene, and regorafenib were purchased from Sigma Aldrich or
selleckchem.com.
+ Open protocol
+ Expand
2

Senolytic Activity of HU-600 and HU-585

Check if the same lab product or an alternative is used in the 5 most similar protocols
In vitro senolytic studies were performed using Navitoclax (ABT-263) dissolved in DMSO (Sigma-Aldrich, Rehovot, Israel). SK-N-SH cells (2 × 104 cells/well) were plated in triplicates in 96-well plates (200 µL) and were cultured according to the previously described regimen, with increasing concentrations of HU-600 or HU-585 (0–200 µM) for 48 h. Subsequently, cells were cultured with ABT-263 (2.5 µM) for 24 h, then an MTT test was performed according to the MTT assay mentioned above. ABT-263 concentration was chosen following several dose response MTT assays. The maximal dose with no effect on survival was 2.5 µM (data not shown).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!